














































|
PREGNANCY
THROMBOPROPHYLAXIS
|
Agents for
Thromboprophylaxis
|
Low molecular weight heparin
|
N Engl J
Med. 1995 May 18;332(20):1330-5.
Heparin-induced thrombocytopenia in patients treated with
low-molecular-weight heparin or unfractionated heparin.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton
JG.
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
BACKGROUND. Heparin-induced thrombocytopenia, defined by the presence of
heparin-dependent IgG antibodies, typically occurs five or more days after
the start of heparin therapy and can be complicated by thrombotic events.
The frequency of heparin-induced thrombocytopenia and of heparin-dependent
IgG antibodies, as well as the relative risk of each in patients given
low-molecular-weight heparin, is unknown. METHODS. We obtained daily
platelet counts in 665 patients in a randomized, double-blind clinical trial
comparing unfractionated heparin with low-molecular-weight heparin as
prophylaxis after hip surgery. Heparin-induced thrombocytopenia was defined
as a decrease in the platelet count below 150,000 per cubic millimeter that
began five or more days after the start of heparin therapy, and a positive
test for heparin-dependent IgG antibodies. We also tested a representative
subgroup of 387 patients for heparin-dependent IgG antibodies regardless of
their platelet counts. RESULTS. Heparin-induced thrombocytopenia occurred in
9 of 332 patients who received unfractionated heparin and in none of 333
patients who received low-molecular-weight heparin (2.7 percent vs. 0
percent; P = 0.0018). Eight of the 9 patients with heparin-induced
thrombocytopenia also had one or more thrombotic events (venous in 7 and
arterial in 1), as compared with 117 of 656 patients without heparin-induced
thrombocytopenia (88.9 percent vs. 17.8 percent; odds ratio, 36.9; 95
percent confidence interval, 4.8 to 1638; P < 0.001). In the subgroup of 387
patients, the frequency of heparin-dependent IgG antibodies was higher among
patients who received unfractionated heparin (7.8 percent, vs. 2.2 percent
among patients who received low-molecular-weight heparin; P = 0.02).
CONCLUSIONS. Heparin-induced thrombocytopenia, associated thrombotic events,
and heparin-dependent IgG antibodies are more common in patients treated
with unfractionated heparin than in those treated with low-molecular-weight
heparin.

 |